<DOC>
	<DOCNO>NCT00553462</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Erlotinib may make tumor cell sensitive radiation therapy . Giving carboplatin paclitaxel albumin-stabilized nanoparticle formulation together radiation therapy erlotinib may kill tumor cell . PURPOSE : This phase II trial study well give carboplatin paclitaxel albumin-stabilized nanoparticle formulation together radiation therapy erlotinib work treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed Radiation Therapy Erlotinib Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine activity induction chemotherapy comprise carboplatin paclitaxel albumin-stabilized nanoparticle formulation follow concurrent thoracic radiotherapy erlotinib hydrochloride patient poor-risk , unresectable stage IIIA IIIB non-small cell lung cancer . Secondary - To determine response rate progression-free survival patient . OUTLINE : Patients receive induction chemotherapy comprise paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 8 carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 2 course . Patient rapid disease progression outside chest induction therapy remove study . Patients intrathoracic disease progression within potential radiation field may continue protocol therapy discretion Study Chair . Patients disease progression outside plan radiation field ( either regional distant ) proceed concurrent erlotinib hydrochloride radiotherapy . Beginning day 43 ( week 7 ) , patient receive oral erlotinib hydrochloride daily . Patients also undergo concurrent radiotherapy 5 day week 7 week ( 33 fraction ) absence rapid disease progression outside chest unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year , every 6 month 2 year</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow histology : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Must meet follow criterion : T13 N2 select N3* T4 N0 , N1 , N2 select N3* M0 ( M1 patient ) NOTE : *Patients contralateral mediastinal disease ( i.e. , N3 ) eligible , provide gross disease encompass within radiation boost field accordance homogeneity criterion . Patients ipsilateral scalene supraclavicular disease also eligible . Patients contralateral hilar supraclavicular node involvement eligible . Must measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Nonmeasurable lesion include follow : Bone lesion Leptomeningeal disease Ascites Pleural pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area Patients must consider unresectable inoperable AND deemed candidate combine modality therapy medical oncologist radiation oncologist Considered poorrisk NCI CTC performance status ( PS ) 2 OR PS 01 ≥ 10 % weight loss within past 3 month Patients tumor adjacent vertebral body eligible , provide gross disease encompass within radiation boost field accordance homogeneity criterion Pleural effusion meet follow criterion allow : Effusion transudate , cytologically negative , nonbloody Effusion see chest CT scan chest xray AND small tap Effusion appear thoracotomy invasive thoracic procedure attempt PATIENT CHARACTERISTICS : See Disease Characteristics Granulocytes ≥ 1,500/μL Platelet count ≥ 100,000/μL Creatinine ≤ 1.5 x upper limit normal ( ULN ) AST &lt; 2 x ULN Bilirubin ≤ ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy NSCLC At least 2 week since formal exploratory thoracotomy No concurrent administration sucralfate suspension erlotinib hydrochloride No concurrent intensitymodulated radiotherapy No concurrent hormone chemotherapeutic agent except steroid give adrenal failure , hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent use dexamethasone antiemetic No concurrent palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>